Next crop of COVID-19 vaccine developers take more traditional route
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat
October 29, 2020 7:48 AM EDTModerna (NASDAQ: MRNA) reported Q3 EPS of ($0.59), $0.16 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $157.91 million versus the consensus estimate of $77.51 million.
The Moderna team continued to execute on our plan in the third quarter. We now have... More
